http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
-
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetin
-
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
-
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
-
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
-
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
-
BioLineRx (BLRX) Reports Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide
-
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
-
BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
-
BioLineRx (BLRX) Announces FDA Approval of APHEXDA in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with
-
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in P
-
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
-
BioLineRx to Report Second Quarter 2023 Results on August 30, 2023
-
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investi
-
BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update
-
BioLineRx (BLRX) Begins Phase 1b Clinical Trial in Patients with ARDS Secondary to COVID-19 & Other Respiratory Viral Infections
-
BioLineRx to Report Third Quarter 2020 Results on November 23, 2020
-
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections
-
BioLineRx (BLRX) Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide in Stem Cell Mobilization
-
BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
-
BioLineRx (BLRX) Begins Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
-
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
-
BioLineRx (BLRX) Reports Target Patient Enrollment in Phase 3 GENESIS Trial for Planned Interim Analysis
-
BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis
-
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
-
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
-
BioLineRx (BLRX) Reports 2.51M ADS Registered Direct Offering at $1.75/ADS
-
BioLineRx Announces $4.39 Million Registered Direct Offering
-
BioLineRx (BLRX) Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
-
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
-
BioLineRx (BLRX) Announces $9 Million Registered Direct Offering of ADSs, Warrants
-
BioLineRx Announces $9.0 Million Registered Direct Offering
-
BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update
-
BioLineRx to Report First Quarter 2020 Results on May 20, 2020
-
BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
-
BioLineRx to Report Annual 2019 Results on March 12, 2020
-
BioLineRx (BLRX) Announces Notice of Allowance from USPTO Covering Motixafortide in Combination With Anti-PD-1 for Treatment of Any Type of Cancer
-
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
-
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
-
BioLineRx (BLRX) Receives Orphan Drug Designation for Motixafortide for Treatment of Pancreatic Cancer in Europe
-
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
-
BioLineRx to Present at the 2020 Biotech Showcase
-
BioLineRx (BLRX) Reports Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study
-
BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
-
BioLineRx (BLRX) Reports Prelim. Ph. 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer
-
BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer
-
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York
-
BioLineRx Reports Third Quarter 2019 Financial Results and Provides Corporate Update
-
BioLineRx to Report Third Quarter 2019 Results on November 11, 2019
-
BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients